Enzymotec (NASDAQ: ENZY) is one of 34 publicly-traded companies in the “Commodity Chemicals” industry, but how does it weigh in compared to its peers? We will compare Enzymotec to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.
This table compares Enzymotec and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Enzymotec has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Enzymotec’s peers have a beta of 1.17, indicating that their average stock price is 17% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Enzymotec and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Enzymotec presently has a consensus target price of $8.00, suggesting a potential downside of 27.93%. As a group, “Commodity Chemicals” companies have a potential downside of 0.72%. Given Enzymotec’s peers stronger consensus rating and higher possible upside, analysts plainly believe Enzymotec has less favorable growth aspects than its peers.
Institutional & Insider Ownership
28.0% of Enzymotec shares are held by institutional investors. Comparatively, 69.0% of shares of all “Commodity Chemicals” companies are held by institutional investors. 8.3% of shares of all “Commodity Chemicals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Enzymotec and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Enzymotec||$47.01 million||-$4.56 million||-38.28|
|Enzymotec Competitors||$4.15 billion||$892.82 million||33.62|
Enzymotec’s peers have higher revenue and earnings than Enzymotec. Enzymotec is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Enzymotec peers beat Enzymotec on 10 of the 12 factors compared.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with our FREE daily email newsletter.